Orphan Synergy Europe (OSE) Pharma SA came out of the starting gate with a Phase II candidate, in-licensing a therapeutic cancer vaccine discovered at San Diego-based Epimmune Inc. that had languished following that company's 2005 merger with Immuno-Designed Molecules (IDM) SA, of Paris.